Vol 6, Supplement 5 (October 15, 2014): Journal of Thoracic Disease (New Lung Adenocarcinoma Classification)

Review Article

Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS)
Elizabeth R. Tang, Andrew M. Schreiner, Bradley B. Pua
Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification
Swaroop Revannasiddaiah, Priyanka Thakur, Bhaskar Bhardwaj, Sridhar Papaiah Susheela, Irappa Madabhavi
The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects
Jon Zugazagoitia, Ana Belen Enguita, Juan Antonio Nuñez, Lara Iglesias, Santiago Ponce
The revised lung adenocarcinoma classification—an imaging guide
Natasha Gardiner, Sanjay Jogai, Adam Wallis
Validation of the new IASLC/ATS/ERS lung adenocarcinoma classification: a surgeon’s perspective
Raffaele Rocco, David R. Jones, Alessandro Morabito, Renato Franco, Elvira La Mantia, Gaetano Rocco
The IASLC/ATS/ERS classification of lung adenocarcinoma-a surgical point of view
Wentao Fang, Yangwei Xiang, Chenxi Zhong, Qunhui Chen
The lung adenocarcinoma guidelines: what to be considered by surgeons
Rodrigo A. S. Sardenberg, Evandro Sobroza Mello, Riad N. Younes
Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts
Ming-Ching Lee, Kyuichi Kadota, Daniel Buitrago, David R. Jones, Prasad S. Adusumilli
Reclassification of early stage pulmonary adenocarcinoma and its consequences
Annikka Weissferdt, Cesar A. Moran
The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management
Yong Tang, Zhe He, Qihang Zhu, Guibin Qiao

Disclosure:

The supplement “New Lung Adenocarcinoma Classification” was commissioned by the editorial office, Journal of Thoracic Disease without any sponsorship or funding. Guibin Qiao served as the unpaid Guest Editor for the supplement.